AQST · Aquestive Therapeutics, Inc. · Documents
$4.05
+0.22 (+5.74%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$512.80M
Shares
125.51M
Volume · Oct 20
2.25M
Avg daily vol (3M)
2.77M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | On October 15, 2026, Aquestive Therapeutics, Inc.’s Board adopted amended and restated bylaws, eliminating a disclosure requirement concerning certain relationships and revising the definition of “Stockholder Associated Person” to exclude persons “acting in concert.” | 2026-10-19 | 2026-10-15 | |
| 8-K | Aquestive announced the FDA accepted its Anaphylm NDA resubmission as complete and classified it as a Class 2 response, setting a PDUFA goal date of March 16, 2027. | 2026-10-15 | — | |
| 8-K | Aquestive licensed Eton exclusive U.S. commercialization rights to LIBERVANT, receiving $10.0 million upfront, up to $47.5 million in milestones and mid-teens royalties, while serving as exclusive manufacturer under a 20-year supply agreement. | 2026-10-14 | 2026-10-13 | |
| 8-K | — | 2026-09-29 | — | |
| 8-K | — | 2026-09-25 | 2026-09-23 | |
| 8-K | — | 2026-09-17 | 2026-09-14 | |
| 8-K | — | 2026-08-11 | — | |
| 10-Q | — | 2026-08-11 | 2026-06-30 | |
| 8-K | — | 2026-08-10 | — | |
| S-3 | — | 2026-06-26 | — | |
| 8-K | — | 2026-06-10 | — | |
| 10-Q | — | 2026-05-13 | 2026-03-31 | |
| 8-K | — | 2026-05-13 | 2026-05-12 | |
| DEFA14A | — | 2026-04-24 | — | |
| DEF 14A | — | 2026-04-24 | 2026-06-10 | |
| ARS | — | 2026-04-24 | 2025-12-31 | |
| 8-K | — | 2026-03-30 | — | |
| 8-K | — | 2026-03-20 | 2026-03-16 | |
| 10-K | — | 2026-03-04 | 2025-12-31 | |
| 8-K | — | 2026-03-04 | 2026-03-03 | |
| 8-K | — | 2026-02-26 | — | |
| 8-K | — | 2026-02-02 | 2026-01-30 | |
| 8-K | — | 2026-01-09 | — | |
| 8-K | — | 2025-11-06 | — | |
| 10-Q | — | 2025-11-05 | 2025-09-30 | |
| 8-K | — | 2025-11-05 | — | |
| 8-K | — | 2025-10-08 | — | |
| 8-K | — | 2025-10-01 | — | |
| 8-K | — | 2025-09-08 | — | |
| 8-K | — | 2025-09-04 | — | |
| 8-K | — | 2025-08-15 | 2025-08-14 | |
| 8-K | — | 2025-08-14 | 2025-08-13 | |
| 8-K | — | 2025-08-11 | — | |
| 10-Q | — | 2025-08-11 | 2025-06-30 | |
| 8-K | — | 2025-07-15 | — | |
| 8-K | — | 2025-06-16 | 2025-06-13 | |
| 8-K | — | 2025-06-11 | — | |
| 8-K | — | 2025-06-02 | — | |
| 8-K | — | 2025-05-12 | — | |
| 10-Q | — | 2025-05-12 | 2025-03-31 | |
| DEF 14A | — | 2025-04-25 | 2025-06-11 | |
| ARS | — | 2025-04-25 | 2024-12-31 | |
| DEFA14A | — | 2025-04-25 | — | |
| 8-K | — | 2025-04-01 | — | |
| 8-K | — | 2025-03-10 | — | |
| 8-K | — | 2025-03-05 | — | |
| 10-K | — | 2025-03-05 | 2024-12-31 | |
| 8-K | — | 2025-02-12 | — | |
| 8-K | — | 2025-01-13 | — | |
| 8-K | — | 2024-12-19 | — |
Showing 1–50 of 213 filings
Key facts
CIK
1398733
CUSIP
03843E104
13F (30d)
14 filings
14 filers
Visit website
Investor relations